Das S, Johnson D. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J for ImmunoTherapy of Cancer. 2019;7:306.

Article  Google Scholar 

Schneider B, Naidoo J, Santomasso B, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073–126.

Article  CAS  PubMed  Google Scholar 

Thompson J, Schneider B, Brahmer J, et al. Management of immunotherapy-related toxicities version 1.2020, featured updatets to the NCCN Guidelines. JNCCN.org. 2020;18(3):230–41.

CAS  Google Scholar 

Beardslee T, Draper A, Kudchadkar R, et al. Tacrolimus for the treatment of immune-related adverse effects refractory to systemic steroids and anti-tumor necrosis factor α -therapy. J Onc Pharm Pract. 2019;25(5):1275–81.

Article  CAS  Google Scholar 

Kunogi Y, Tominaga K, Abe K, et al. Refractory immune checkpoint inhibitor-induced colitis improved by tacrolimus: a case report. Healthcare. 2021;9:418.

Article  PubMed  PubMed Central  Google Scholar 

Collins M, Soularue E, Carbonnel F. Management of patients with immune checkpoint inhibitor-induced enterocolitis: a systematic review. Clin Gastroenterol Hepatol. 2020;18:1393–403.

Article  CAS  PubMed  Google Scholar 

Abu-Sbeih H, Ali FS, Naqash AR, et al. Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J of Clinic Oncol. 2019;37(30):2738–45.

Article  CAS  Google Scholar 

Nogal G, Patel N. Refractory checkpoint inhibitor colitis responsive to Ustekinumab. ACG Case Rep J. 2022;9:e00946.

Article  Google Scholar 

Mir R, Shaw HM, Nathan PD. Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis. Melanoma Res. 2019;29(1):102–6.

Article  CAS  PubMed  Google Scholar 

Abu-Sbeih H, Ali FS, Alsaadi D, et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer. 2018;67:2056–67.

Google Scholar 

Ishihara H, Watanabe T, Kumei S, et al. A case of refractory immune checkpoint inhibitor-induced colitis improved by the treatment with vedolizumab and granulocyte-monocyte apheresis combination therapy. Clin J of Gastroenterol. 2023. https://doi.org/10.1007/s12328-023-01887-7.

Article  Google Scholar 

Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmaco. 1995;29:404–30.

Article  CAS  Google Scholar 

Zhang E, Kiely C, Sandanayake N, et al. Calcineurin inhibitors in steroid and anti-TNF-alpha refractory immune checkpoint inhibitor colitis. JGH Open. 2021. https://doi.org/10.1002/jgh3.12531.

Article  PubMed  PubMed Central  Google Scholar 

Powell N, Ibraheim H, Raine T, et al. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. Lancet Gastroenterol Hepatol. 2020;5:679–97.

Article  PubMed  Google Scholar 

Wang DY, Kim DW, Shah NJ, et al. Clinical presentation of immune-related colitis associated with PD-1 inhibitor monotherapy(MONO) and combination PD-1/CTLA-4 inhibitors(COMBO) in melanoma. Proc Am Soc Clin Oncol. 2017;35:9566.

Article  Google Scholar 

Kikuchi H, Sakuraba H, Akemoto Y, et al. A case of nivolumab-associated colitis, which relapsed after mucosal healing and was then successfully treated with mesalazine. Immunol Med. 2019;42:39–44.

Article  PubMed  Google Scholar 

Christensen B, Gibson P, Micic D, et al. Effectiveness of calcineurin inhibitors with vedolizumab in refractory inflammatory bowel disease. Clin Gastroenterol Hepatol. 2019;17(3):486–93.

Article  CAS  PubMed  Google Scholar